Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterprise Therapeutics Publishes Paper on Novel Therapeutic Approach for Treatment of All Cystic Fibrosis Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterprise Therapeutics Doses First Subjects in Phase 1 Trial for First-in-Class Cystic Fibrosis Therapy ETD002","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$96.8 milion","newsHeadline":"Enterprise Therapeutics\u2019 TMEM16A Potentiator Program for Treatment of Cystic Fibrosis and Other Respiratory Diseases Acquired by Roche","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterprise Therapeutics Doses First Subjects in Phase I Trial for Novel Cystic Fibrosis Therapy ETD001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Panakes Partners","pharmaFlowCategory":"D","amount":"$33.1 million","upfrontCash":"Undisclosed","newsHeadline":"Enterprise Therapeutics Closes \u00a326 million ($33.1 million) Series B Follow-on Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Enterprise Therapeutics

    Menu

    Enterprise Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Enterprise Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing

              Details:

              The financing will fund the Phase 2a clinical trial of the Company’s lead programme, ETD001, a novel first in class ENaC blocker, to deliver clinical proof of concept to treat cystic fibrosis.

              Lead Product(s): ETD001

              Therapeutic Area: Genetic Disease Product Name: ETD001

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Panakes Partners

              Deal Size: $33.1 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing January 30, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Enterprise Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Enterprise Therapeutics Doses First Subjects in Phase I Trial for Novel Cystic Fibrosis Therapy ETD001

              Details:

              By increasing the amount of airway fluid available to hydrate mucus, ETD001 addresses the underlying mechanisms of mucus congestion, and is expected to restore lung function, reduce the frequency of lung infections and improve patient quality of life.

              Lead Product(s): ETD001

              Therapeutic Area: Genetic Disease Product Name: ETD001

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 14, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Enterprise Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Enterprise Therapeutics’ TMEM16A Potentiator Program for Treatment of Cystic Fibrosis and Other Respiratory Diseases Acquired by Roche

              Details:

              Enterprise Therapeutics' TMEM16A portfolio includes ETD002, first of its compounds to hit clinical stage. In pre-clinical models the compound has been found to enhances the activity of TMEM16A.

              Lead Product(s): ETD002

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ETD002

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

              Deal Size: Undisclosed Upfront Cash: $96.8 milion

              Deal Type: Acquisition October 07, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Enterprise Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Enterprise Therapeutics Doses First Subjects in Phase 1 Trial for First-in-Class Cystic Fibrosis Therapy ETD002

              Details:

              ETD002. The first-in-man safety study is being conducted in healthy participants with ETD002, a TMEM16A potentiator aimed at treating all people with cystic fibrosis (CF).

              Lead Product(s): ETD002

              Therapeutic Area: Genetic Disease Product Name: ETD002

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 17, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Enterprise Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Enterprise Therapeutics Publishes Paper on Novel Therapeutic Approach for Treatment of All Cystic Fibrosis Patients

              Details:

              Paper demonstrates first in class TMEM16A chloride channel potentiators, to accelerate mucociliary clearance.

              Lead Product(s): ETX001

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY